1
|
Fernández-Arce L, Robles-Rodríguez N, Fernández-Feito A, Fernández-Iglesias R, Fernández-Álvarez MDM, Lana A. Impact of Breast Cancer on Cardiometabolic Health in Spanish Women ≥50 Years with Pre-Existing Type 2 Diabetes Mellitus. Cancers (Basel) 2024; 16:2853. [PMID: 39199624 PMCID: PMC11352853 DOI: 10.3390/cancers16162853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 08/03/2024] [Accepted: 08/13/2024] [Indexed: 09/01/2024] Open
Abstract
During breast cancer (BC), cardiometabolic disorders can worsen prognosis, particularly in women with type 2 diabetes mellitus (T2DM). This study aimed to determine the impact of BC diagnosis on cardiometabolic parameters and the incidence of complication in women over 50 years of age (90% aged ≥ 65 years) with pre-existing T2DM. Using primary care registries from Asturias (Spain), a total of 106 women diagnosed with T2DM followed by BC were selected and matched with women with T2DM (n = 212) in a cohort study. Indicators of cardiometabolic health and microvascular complications associated with T2DM were collected. Women were monitored from two years prior to five years after BC diagnosis. Conditional logistic regressions were used to compare the adjusted odds of staying below each indicator's threshold. During follow-up, women with T2DM+BC had a higher risk of fasting blood glucose ≥126 mg/dL (adjusted odds ratio [aOR] = 1.83; 95% confidence interval [CI95%]: 1.01-3.32) and glycosylated hemoglobin (Hb1Ac) ≥ 48 mmol/mol or 6.5% (aOR: 2.44; IC95%: 1.21-4.91). There was no difference between the groups regarding the incidence of microvascular complications. BC incidence negatively impacted the glycemic control of Spanish women with pre-existing T2DM measured by basal blood glucose and HbA1c, but not cardiometabolic health indicators or T2DM complications.
Collapse
Affiliation(s)
- Lucía Fernández-Arce
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain; (N.R.-R.); (A.F.-F.); (R.F.-I.); (A.L.)
| | - Nena Robles-Rodríguez
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain; (N.R.-R.); (A.F.-F.); (R.F.-I.); (A.L.)
| | - Ana Fernández-Feito
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain; (N.R.-R.); (A.F.-F.); (R.F.-I.); (A.L.)
| | - Rocío Fernández-Iglesias
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain; (N.R.-R.); (A.F.-F.); (R.F.-I.); (A.L.)
| | - María del Mar Fernández-Álvarez
- Department of Surgery and Medical Surgical Specialities, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain;
| | - Alberto Lana
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Oviedo/ISPA, 33006 Oviedo, Spain; (N.R.-R.); (A.F.-F.); (R.F.-I.); (A.L.)
| |
Collapse
|
2
|
Shiba S, Harao M, Saito A, Sakuragi M, Kitayama J, Sata N. Metformin Alters Tumor Immune Microenvironment, Improving the Outcomes of Breast Cancer Patients With Type 2 Diabetes Mellitus. J Breast Cancer 2024; 27:121-129. [PMID: 38529589 PMCID: PMC11065500 DOI: 10.4048/jbc.2023.0285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 01/25/2024] [Accepted: 02/06/2024] [Indexed: 03/27/2024] Open
Abstract
This study investigated the clinical effect of metformin on breast cancer patients with preexisting type 2 diabetes mellitus (T2DM). We analyzed 177 patients with T2DM who underwent breast cancer surgery and assessed tumor-associated macrophages (TAMs) and tumor-infiltrating lymphocytes (TILs) in patients who underwent tumor resection with or without metformin treatment using multiplex immunohistochemistry (IHC). Patients who received metformin either pre- or postoperatively exhibited reduced distant organ recurrence and improved postoperative recurrence-free survival compared to those of patients who did not. Additionally, in a subgroup of 40 patients receiving preoperative systemic therapy, metformin treatment was associated with increased rates of pathological complete response. IHC analysis revealed significantly lower levels of cluster of differentiation (CD) 68(+) CD163(+) M2-type TAMs (p < 0.01) but higher CD3(+) and CD8(+) TIL densities in the metformin-treated group compared with the same parameters in those without metformin treatment, with a significant difference in the CD8(+)/CD3(+) TIL ratio (p < 0.01). Despite the constraints posed by our small sample size, our findings suggest a potential role for metformin in modulating the immunological microenvironment, which may contribute to improved outcomes in diabetes patients with breast cancer.
Collapse
Affiliation(s)
- Satomi Shiba
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
- Department of Breast Oncology, Jichi Medical University Hospital, Shimotsuke, Japan
| | - Michiko Harao
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
- Department of Breast Oncology, Jichi Medical University Hospital, Shimotsuke, Japan
| | - Akira Saito
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
| | - Masako Sakuragi
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
- Department of Breast Oncology, Jichi Medical University Hospital, Shimotsuke, Japan
| | - Joji Kitayama
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
- Department of Breast Oncology, Jichi Medical University Hospital, Shimotsuke, Japan.
| | - Naohiro Sata
- Department of Surgery, Jichi Medical University, Shimotsuke, Japan
| |
Collapse
|
3
|
Garczorz W, Kosowska A, Francuz T. Antidiabetic Drugs in Breast Cancer Patients. Cancers (Basel) 2024; 16:299. [PMID: 38254789 PMCID: PMC10813754 DOI: 10.3390/cancers16020299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 01/06/2024] [Accepted: 01/08/2024] [Indexed: 01/24/2024] Open
Abstract
Diabetes is one of the leading chronic conditions worldwide, and breast cancer is the most prevalent cancer in women worldwide. The linkage between diabetes and its ability to increase the risk of breast cancer should always be analyzed in patients. This review focuses on the impact of antihyperglycemic therapy in breast cancer patients. Patients with diabetes have a higher risk of developing cancer than the general population. Moreover, diabetes patients have a higher incidence and mortality of breast cancer. In this review, we describe the influence of antidiabetic drugs from insulin and metformin to the current and emerging therapies, incretins and SGLT-2 inhibitors, on breast cancer prognosis. We also emphasize the role of obesity and the metastasis process in breast cancer patients who are treated with antidiabetic drugs.
Collapse
Affiliation(s)
- Wojciech Garczorz
- Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-055 Katowice, Poland; (A.K.); (T.F.)
| | | | | |
Collapse
|
4
|
Huo Q, Wang S, Hou Y, Gorczynski RM, Shen Y, Wang B, Ge H, Li T. Editorial: The relationship between diabetes and cancers and its underlying mechanisms, volume II. Front Endocrinol (Lausanne) 2024; 14:1357577. [PMID: 38292767 PMCID: PMC10826604 DOI: 10.3389/fendo.2023.1357577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 12/21/2023] [Indexed: 02/01/2024] Open
Affiliation(s)
- Qiang Huo
- Clinical Research Center, Nanjing Jiangbei Hospital, Nanjing, China
- Center for Translational Medicine, Zibo Central Hospital, Zibo, China
| | - Shuo Wang
- Department of Oncology, Shibo High-Tech Hospital, Zibo, China
| | - Ying Hou
- Department of Otolaryngology, Zibo Central Hospital, Zibo, China
| | | | - Yining Shen
- College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China
| | - Bin Wang
- Department of Oncology, Zibo First Hospital, Zibo, China
| | - Hanyi Ge
- Department of Stomatology, Zibo Central Hospital, Zibo, China
| | - Tao Li
- Clinical Research Center, Nanjing Jiangbei Hospital, Nanjing, China
| |
Collapse
|
5
|
Xiong F, Dai Q, Zhang S, Bent S, Tahir P, Van Blarigan EL, Kenfield SA, Chan JM, Schmajuk G, Graff RE. Diabetes and incidence of breast cancer and its molecular subtypes: A systematic review and meta-analysis. Diabetes Metab Res Rev 2024; 40:e3709. [PMID: 37545374 DOI: 10.1002/dmrr.3709] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Revised: 05/05/2023] [Accepted: 07/12/2023] [Indexed: 08/08/2023]
Abstract
Diabetes mellitus (DM) has been proposed to be positively associated with breast cancer (BCa) risk due to shared risk factors, metabolic dysfunction, and the use of antidiabetic medications. We conducted a systematic review and meta-analysis to evaluate the association between DM and BCa risk. We searched PubMed, Embase, and Web of Science for cohort and case-control studies assessing the association between DM and BCa published before 10 December 2021. Two reviewers independently screened the studies for inclusion, abstracted article data, and rated study quality. Random effects models were used to estimate summary risk ratios (RRs) and 95% confidence intervals (CIs). From 8396 articles identified in the initial search, 70 independent studies were included in the meta-analysis. DM was associated with an overall increased risk of BCa (RR = 1.20, 95% CI: 1.11-1.29). The 24 case-control studies demonstrated a stronger association (RR = 1.26, 95% CI: 1.13-1.40) than the 46 cohort studies (RR = 1.15, 95% CI: 1.05-1.27). Studies reporting risk by menopausal status found that postmenopausal women had an elevated risk of developing BCa (RR = 1.12, 95% CI: 1.07-1.17). No association between DM and BCa risk was observed among premenopausal women (RR = 0.95, 95% CI: 0.85-1.05). In addition, DM was associated with significantly increased risks of oestrogen receptor (ER)+ (RR = 1.09, 95% CI: 1.00-1.20), ER- (RR = 1.16, 95% CI: 1.04-1.30), and triple negative BCa (RR = 1.41, 95% CI: 1.01-1.96). The association estimate for human epidermal growth factor 2-positive BCa was also positive (RR = 1.21, 95% CI: 0.52-2.82), but the CI was wide and crossed the null. Our meta-analysis confirms a modest positive association between DM and BCa risk. In addition, our results suggest that the association between DM and BCa may be modified by menopausal status, and that DM may be differentially associated with BCa subtypes defined by receptor status. Additional studies are warranted to investigate the mechanisms underlying these associations and any influence of DM on BCa receptor expression.
Collapse
Affiliation(s)
- Fanxiu Xiong
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
| | - Qichen Dai
- Department of Breast Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Sihan Zhang
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Stephen Bent
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
- Department of Psychiatry, University of California, San Francisco, San Francisco, California, USA
| | - Peggy Tahir
- UCSF Library, University of California, San Francisco, San Francisco, California, USA
| | - Erin L Van Blarigan
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
- Department of Urology, University of California, San Francisco, San Francisco, California, USA
| | - Stacey A Kenfield
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
- Department of Urology, University of California, San Francisco, San Francisco, California, USA
| | - June M Chan
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
- Department of Urology, University of California, San Francisco, San Francisco, California, USA
| | - Gabriela Schmajuk
- Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
| | - Rebecca E Graff
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
| |
Collapse
|
6
|
Matou-Nasri S, Aldawood M, Alanazi F, Khan AL. Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy. Diagnostics (Basel) 2023; 13:2390. [PMID: 37510134 PMCID: PMC10378597 DOI: 10.3390/diagnostics13142390] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 06/20/2023] [Accepted: 06/26/2023] [Indexed: 07/30/2023] Open
Abstract
Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by the lack of expression for estrogen receptors and progesterone receptors, and the absence of epidermal growth factor receptor (HER)2 amplification. Corresponding to 15-20% of all breast cancers and well-known by its poor clinical outcome, this negative receptor expression deprives TNBC from targeted therapy and makes its management therapeutically challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic disorder due to insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, there are many interplays between both chronic disorders leading to increased risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose of this review is to provide up-to-date information related to epidemiology and clinicopathological features, risk factors, diagnosis, biomarkers, and current therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic counterparts. Thus, in-depth investigation of the diabetic complications on TNBC onset, development, and progression and the discovery of biomarkers would improve TNBC management through early diagnosis, tailoring therapy for a better outcome of T2DM patients diagnosed with TNBC.
Collapse
Affiliation(s)
- Sabine Matou-Nasri
- Blood and Cancer Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, Saudi Arabia
- Biosciences Department, Faculty of the School for Systems Biology, George Mason University, Manassas, VA 22030, USA
| | - Maram Aldawood
- Blood and Cancer Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, Saudi Arabia
- Post Graduate and Zoology Department, King Saud University, Riyadh 12372, Saudi Arabia
| | - Fatimah Alanazi
- Blood and Cancer Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, Saudi Arabia
- Biosciences Department, Faculty of the School for Systems Biology, George Mason University, Manassas, VA 22030, USA
| | - Abdul Latif Khan
- Tissue Biobank, KAIMRC, MNG-HA, Riyadh 11481, Saudi Arabia
- Pathology and Clinical Laboratory Medicine, King Abdulaziz Medical City (KAMC), Riyadh 11564, Saudi Arabia
| |
Collapse
|
7
|
Lao C, Gurney J, Stanley J, Krebs J, Meredith I, Campbell I, Teng A, Sika-Paotonu D, Koea J, Lawrenson R. Association of diabetes and breast cancer characteristics at diagnosis. Cancer Causes Control 2023; 34:103-111. [PMID: 36409455 DOI: 10.1007/s10552-022-01654-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/09/2022] [Indexed: 11/22/2022]
Abstract
PURPOSE This study aims to examine the association of diabetes and breast cancer characteristics at diagnosis in Aotearoa/New Zealand. METHODS Patients diagnosed with invasive breast cancer between 2005 and 2020 were identified from the National Breast Cancer Register. Logistic regression modeling was used to estimate the adjusted odds ratio (OR) of having stage III-IV cancer and the OR of having stage IV cancer for women with diabetes compared to those without diabetes. The adjusted OR of having screen-detected breast cancers for patients aged 45-69 years with diabetes compared to patients without diabetes was estimated. RESULTS 26,968 women were diagnosed with breast cancer, with 3,137 (11.6%) patients having diabetes at the time of cancer diagnosis. The probability of co-occurrence of diabetes and breast cancer increased with time. Māori, Pacific and Asian women were more likely to have diabetes than European/Others. The probability of having diabetes also increased with age. For patients with diabetes, the probability of being diagnosed with stage III-IV cancer and stage IV cancer was higher than for patients without diabetes (OR 1.14, 95% CI 1.03-1.27; and 1.17, 95% CI 1.00-1.38). Women aged 45-69 years with diabetes were more likely to have screen-detected cancer than those without diabetes (OR 1.13, 95% CI 1.02-1.26). CONCLUSIONS The co-occurrence of diabetes and breast cancer is becoming more common. Overall there is a small but significant adverse impact of having advanced disease for women with diabetes that is found at the time of breast cancer diagnosis, and this may contribute to other inequities that occur in the treatment pathway that may impact on patient outcomes.
Collapse
Affiliation(s)
- Chunhuan Lao
- Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand.
| | - Jason Gurney
- Department of Public Health, University of Otago, Wellington, New Zealand
| | - James Stanley
- Department of Public Health, University of Otago, Wellington, New Zealand
| | - Jeremy Krebs
- Department of Medicine, University of Otago, Wellington, New Zealand
| | - Ineke Meredith
- General Surgery, Wakefield Hospital, Wellington, New Zealand
| | - Ian Campbell
- General Surgery, Wakefield Hospital, Wellington, New Zealand
- School of Medicine, The University of Auckland, Auckland, New Zealand
| | - Andrea Teng
- Department of Public Health, University of Otago, Wellington, New Zealand
| | - Dianne Sika-Paotonu
- Department of Pathology & Molecular Medicine, University of Otago, Wellington, New Zealand
| | - Jonathan Koea
- General Surgery, Wakefield Hospital, Wellington, New Zealand
- Medical Surgery, The University of Auckland, Auckland, New Zealand
| | - Ross Lawrenson
- Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand
- Strategy and Funding, Waikato Hospital, Hamilton, New Zealand
| |
Collapse
|
8
|
Reitz LK, Schroeder J, Raick M, de Fragas Hinnig P, Vieira FGK, De Assis MAA, Da Silva EL, Di Pietro G, Di Pietro PF. Diet Quality Influences the Occurrence of Food Aversions in Women Undergoing Adjuvant Chemotherapy for Breast Cancer. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:13915. [PMID: 36360799 PMCID: PMC9658364 DOI: 10.3390/ijerph192113915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/21/2022] [Accepted: 10/24/2022] [Indexed: 06/16/2023]
Abstract
Food aversions in women undergoing adjuvant chemotherapy for breast cancer may be linked to oxidative stress and gastrointestinal consequences underlying it, and diet possibly plays a role in this association. This follow-up study included 73 women with breast cancer treated in Florianopolis City, Brazil. Dietary antioxidant capacity-DaC (mmol/d), diet quality-Brazilian Healthy Eating Index Revised (BHEI-R score), and oxidative stress biomarkers were accessed before the treatment, and women were asked if they developed food aversions during adjuvant chemotherapy. Red meat was the main aversion-causing food reported (37.9%, n = 9). There was no difference in DaC, BHEI-R score, or oxidative stress biomarkers between women with no food aversion occurrence and those showing food aversions. A logistic regression adjusted model showed that women exhibiting higher BHEI-R scores were 1.08 times more likely to not develop food aversions during adjuvant chemotherapy (p = 0.041). In summary, this innovative investigation showed that diet quality before adjuvant chemotherapy may influence the non-occurrence of food aversion. Considering this, the result opens new areas for early nutritional interventions, focusing on reducing the occurrence of food aversions and consequently benefiting women with breast cancer by having better outcomes in oncologic treatment.
Collapse
Affiliation(s)
- Luiza Kuhnen Reitz
- Post-Graduation Program in Nutrition, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| | - Jaqueline Schroeder
- Post-Graduation Program in Nutrition, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| | - Marina Raick
- Graduation Program in Nutrition, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| | - Patricia de Fragas Hinnig
- Post-Graduation Program in Nutrition, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| | | | | | - Edson Luiz Da Silva
- Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| | - Giuliano Di Pietro
- Pharmacy Department, Federal University of Sergipe, Aracaju 49100000, Brazil
| | - Patricia Faria Di Pietro
- Post-Graduation Program in Nutrition, Federal University of Santa Catarina, Florianópolis 88040900, Brazil
| |
Collapse
|
9
|
Chang YH, Hoang NN, Khanh VC, Yamashita T, Osaka M, Hiramatsu Y, Ohneda O. Type 2 Diabetes Mellitus Promotes the Differentiation of Adipose Tissue-derived Mesenchymal Stem Cells into Cancer-associated Fibroblasts, Induced by Breast Cancer Cells. Stem Cells Dev 2022; 31:659-671. [PMID: 35734905 DOI: 10.1089/scd.2022.0086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
Abstract
Triple Negative Breast Cancer (TNBC) is a highly aggressive and invasive type of breast cancer. In addition, type 2 diabetes mellitus (T2DM) is recognized as a risk factor for cancer metastasis, which is associated with mortality in patients with breast cancer. Cancer-associated fibroblasts (CAFs) generated from adipose tissue-derived mesenchymal stem cells (AT-MSCs) play a vital role in the progression of TNBC. However, to date, whether T2DM affects the ability of AT-MSCs to differentiate into CAFs is still unclear. In the present study, we found that in coculture with TNBC cells (BCCs) under hypoxic conditions, AT-MSCs derived from T2DM donors (dAT-MSCs) were facilitated to differentiate into CAFs, which showed fibroblastic morphology, and the induced expression of fibroblastic markers, such as FAP, FSP and vimentin. This was involved in the higher expression of TGFRand the phosphorylation of Smad2/3. Furthermore, T2DM affected the fate and functions of CAFs derived from dAT-MSCs. While CAFs derived from AT-MSCs of healthy donors (AT-CATs) exhibited the markers of inflammatory CAFs, those derived from dAT-MSCs (dAT-CAFs) showed the markers of myofibroblastic CAFs. Of note, in comparison to AT-CAFs, dAT-CAFs showed a higher ability to induce the proliferation and in vivo metastasis of BCCs, which was involved in the activation of the TGF-Smad2/3 signaling pathway. Collectively, our study suggests that T2DM contributes to metastasis of BCCs by inducing the myofibroblastic CAFs differentiation of dAT-MSCs. In addition, targeting the TGF-Smad2/3 signaling pathway in dAT-MSCs may be useful in cancer therapy for TNBC patients with T2DM.
Collapse
Affiliation(s)
- Yun-Hsuan Chang
- University of Tsukuba, 13121, Regenerative Medicine and Stem Cell Biology, Tsukuba, Ibaraki, Japan;
| | - Ngo Nhat Hoang
- University of Tsukuba, 13121, Regenerative Medicine and Stem Cell Biology, Tsukuba, Ibaraki, Japan;
| | - Vuong Cat Khanh
- University of Tsukuba, Regenerative Medicine, Tsukuba, Japan;
| | | | - Motoo Osaka
- University of Tsukuba, Cardiovascular Surgery, Tsukuba, Japan;
| | - Yuji Hiramatsu
- University of Tsukuba, Cardiovascular Surgery, Tsukuba, Japan;
| | - Osamu Ohneda
- University of Tsukuba, Regenerative Medicine, 1-1-1 Tennoudai, Tsukuba, Japan, 305-8575;
| |
Collapse
|
10
|
Huo Q, Wang J, Zhang N, Xie L, Yu H, Li T. Editorial: The relationship between diabetes and cancers and its underlying mechanisms. Front Endocrinol (Lausanne) 2022; 13:992569. [PMID: 36017321 PMCID: PMC9396273 DOI: 10.3389/fendo.2022.992569] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 07/21/2022] [Indexed: 12/05/2022] Open
Affiliation(s)
- Qiang Huo
- Clinical Research Center, Nanjing Jiangbei Hospital, Nanjing, China
- Center for Translational Medicine, Zibo Central Hospital, Zibo, China
| | - Jing Wang
- Blood Purification Center, Zibo Central Hospital, Zibo, China
| | - Nannan Zhang
- Department of Otolaryngology, Zibo Central Hospital, Zibo, China
| | - Long Xie
- Department of Oncology, Shibo High-Tech Hospital, Zibo, China
- *Correspondence: Tao Li, ; Heshan Yu, ; Long Xie,
| | - Heshan Yu
- Department of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, China
- *Correspondence: Tao Li, ; Heshan Yu, ; Long Xie,
| | - Tao Li
- Clinical Research Center, Nanjing Jiangbei Hospital, Nanjing, China
- *Correspondence: Tao Li, ; Heshan Yu, ; Long Xie,
| |
Collapse
|